Mast cell activation syndrome (MCAS) is not caused by a single inherited gene, but genetics clearly play a role in who develops it. The picture is complex: some forms involve acquired mutations in a single gene, others are linked to an inherited trait carried by roughly 5% of the population, and family studies show the condition clusters in households far more often than chance would predict. Understanding which genetic factors are at work matters because it shapes how the condition is diagnosed and managed.
How MCAS Is Classified
MCAS falls into three broad categories, and the genetic story differs for each. Primary (clonal) MCAS involves mast cells that carry a mutation making them overly active. This mutation, found in a gene called KIT, is somatic, meaning it develops during a person’s lifetime rather than being inherited from a parent. Over 90% of people with the related condition mastocytosis carry this specific KIT mutation, and when MCAS is tied to that same clonal mast cell population, it’s considered primary MCAS.
Secondary MCAS is triggered by an identifiable outside cause, such as an allergy or another medical condition that ramps up mast cell activity. In these cases, the mast cells themselves are genetically normal but are being provoked by something else in the body.
Idiopathic MCAS is the diagnosis when no clonal markers are found and no clear external trigger is identified. This is the category where inherited genetic susceptibility is most actively debated, because something is clearly making these patients’ mast cells hyper-reactive, yet the standard tests come back unremarkable.
The KIT Mutation: Acquired, Not Inherited
The most well-studied genetic change in mast cell disease is a mutation in the KIT gene at position D816V. This mutation acts like a stuck “on” switch, telling mast cells to survive and multiply without the normal signals. It’s found in virtually 100% of adults with indolent systemic mastocytosis when sensitive testing methods are used on bone marrow samples.
This mutation is somatic. It arises spontaneously in a blood cell precursor at some point during life, not in the egg or sperm. You don’t inherit it from your parents, and you won’t pass it to your children through normal reproduction. In rare cases of familial mastocytosis (particularly in children), other KIT mutations have been found, some of which are germline, meaning they were present from conception. But these are uncommon variants at different locations on the gene, not the classic D816V change.
Hereditary Alpha-Tryptasemia: A True Inherited Trait
The clearest genetic link to mast cell symptoms that you can inherit is a condition called hereditary alpha-tryptasemia, or HαT. People with this trait carry extra copies of the TPSAB1 gene, which encodes a protein called alpha-tryptase. More gene copies mean higher baseline tryptase levels in the blood, whether or not a mast cell reaction is happening. The more copies someone inherits, the higher their resting tryptase tends to be.
HαT is surprisingly common. Studies estimate it affects about 5% of the European population, though most carriers have no significant symptoms. It follows an autosomal dominant inheritance pattern, so a parent with the trait has a 50% chance of passing it to each child. Among people with mastocytosis, the prevalence of HαT jumps to about 17%, suggesting it may amplify mast cell symptoms or predispose people to more severe reactions.
Whether HαT alone can cause a standalone form of MCAS is still debated. Patients with the trait typically have baseline tryptase levels above 8 ng/mL, often above 10. This can complicate diagnosis, since elevated tryptase is one of the markers doctors look for when evaluating mast cell activation. Testing for TPSAB1 gene copy number is commercially available in the United States.
MCAS Runs in Families
One of the strongest pieces of evidence for a genetic component comes from family studies. In a German study that surveyed first-degree relatives of patients with mast cell activation disease, about 46% of those relatives reported symptoms consistent with the condition. That’s compared to roughly 17% in the general population, a statistically significant difference. The pattern held across parents, siblings, and children at similar rates, which is consistent with a genetic contribution rather than a shared environmental exposure that might affect only one generation.
Interestingly, the specific subtype and severity of mast cell disease varied between affected family members. Two siblings might both have mast cell problems, but one could have mild flushing and gut symptoms while the other has severe episodes. This variability suggests that while a genetic predisposition is shared, other factors (environmental exposures, additional gene variants, epigenetic changes) shape how the disease actually manifests.
Germline Variants That Increase Susceptibility
A genome-wide association study looking at people with KIT D816V-positive mastocytosis identified several inherited genetic variants that appear to raise susceptibility to the disease. One variant is linked to the expression of CEBPA, a gene encoding a protein critical for the development of certain white blood cells. Additional signals were found near the TPSAB1/TPSB2 region (the tryptase genes), the TERT gene, and IL13, which is involved in allergic immune responses.
These are not mutations that directly cause mast cell disease. They are common genetic variations that slightly shift the odds. Think of them as background factors that make a person’s biology more hospitable to mast cell problems if other triggers come along. This is similar to how certain gene variants increase the risk of asthma or autoimmune disease without guaranteeing someone will develop it.
Epigenetics: Genes Influenced by Environment
Beyond the DNA sequence itself, the way mast cell genes are switched on or off can be altered by environmental factors. This field, called epigenetics, helps explain why genetically similar people can have very different mast cell behavior. Chemical modifications to the proteins that package DNA (histones) can either tighten or loosen access to certain genes, dialing mast cell reactivity up or down.
Research has shown that colonizing gut bacteria, prior infections, dietary components, pollution exposure, and antibiotic use can all shape how the immune system responds to allergens and other triggers. None of these factors alone accounts for why some people develop mast cell activation problems, which points to a layered interaction between inherited genes and lifetime exposures. Animal studies have demonstrated that certain dietary compounds can suppress mast cell function through epigenetic mechanisms, specifically by altering histone acetylation patterns that control inflammatory gene expression.
The Link With Ehlers-Danlos Syndrome and POTS
Clinicians have observed that MCAS frequently appears alongside hypermobile Ehlers-Danlos syndrome (hEDS) and postural orthostatic tachycardia syndrome (POTS), leading many patients to wonder if a shared genetic cause connects all three. As of now, no common biological mechanism linking the triad has been identified. A review of the existing literature found that current evidence is lacking on whether MCAS and hEDS even represent clearly defined, separate clinical entities with measurable overlap, let alone ones with a shared genetic root. The co-occurrence is real in clinical practice, but the “why” remains unresolved.
What Genetic Testing Can Tell You
If you’re being evaluated for a mast cell disorder, two genetic tests are most relevant. The first is testing for the KIT D816V mutation, typically performed on a bone marrow biopsy sample. A positive result points toward clonal mast cell disease (mastocytosis or primary MCAS). The second is TPSAB1 copy number testing for hereditary alpha-tryptasemia, done through a blood sample. There is no single genetic test that diagnoses idiopathic MCAS, because no specific causative gene has been identified for that category.
For people with advanced or aggressive forms of mast cell disease, broader genetic sequencing (next-generation sequencing panels) can identify additional mutations that help predict how the disease will behave and guide treatment decisions. These panels look beyond KIT to other genes involved in blood cell development that may carry relevant changes.
If mast cell problems run in your family, genetic testing for HαT is a reasonable starting point, since it’s the most clearly inherited risk factor with a commercially available test. A positive result won’t confirm MCAS on its own, but it provides useful context for interpreting tryptase levels and understanding your baseline risk.